ACHIKO-LTD.
12.6.2019 10:25:08 CEST | Business Wire | Press release
Achiko Limited, a leading fintech provider in Indonesia, announced today that it plans to submit an application for a direct listing on the SIX Swiss Exchange, Switzerland's principal stock exchange.
Achiko's primary business is Mimopay. Founded in 2012, Mimopay has grown quickly to become a leading provider of payment services in Indonesia for people who do not have a bank account or credit card. People can pay for digital gaming content and services via a range of payment channels, such as telecom billing, game vouchers, and at over 10,000 convenience stores and over 100,000 ATMs.
"We're excited about the future and the opportunities that financial and digital inclusion can bring to the 1.7 billion unbanked adults around the world," said Allen Wu, Chairman of Achiko. "We're inspired by the success of platforms such as WeChat and Kakao, that combine payments with a wide- range of services, and believe that model provides a roadmap for our own global ambitions. We've started with Indonesia and we're expanding our system's digital and physical footprints by accelerating partnerships and diversifying revenue beyond payments."
The Company includes an experienced management team which has worked on and delivered multi-billion US dollar projects at globally-recognized digital businesses for companies such as Disney, Time-Warner, today named WarnerMedia, Samsung, Kakao and Leon Entertainment. With backing from MNC Corporation, Indonesia's largest media group, and MOX, the Mobile Only Accelerator of SOSV the first accelerator group in Asia, Achiko is redefining mobile based social commerce in one of the world's most vibrant consumer markets.
Building on Mimopay's 2 million end-user customers in Indonesia, Achiko intends to expand its payments platform through strategic partnerships in Myanmar, The Philippines and Vietnam, in the next 18 months. "There are many developing countries across the world like Indonesia that have high mobile penetration, yet a large population of unbanked who cannot pay for online services through traditional payment channels," said Kenneth Ting, the CEO of Achiko. "These markets represent tremendous growth opportunities for us."
The company plans to list 100 million shares. Achiko's last round of financing was at a USD $0.70 per share.
About Achiko Limited
The Holding Company was established in 2018, and includes Mimopay (2012), Kryptonite (2014), a licensee for the popular Yabb Messenger. The Company has operations in Indonesia, Korea and Taiwan, and is backed by MNC Corporation, the largest media company in Indonesia, and MOX, the Mobile Only Accelerator of SOSV -- the first mobile-focused accelerator in Asia.
For more information please visit: www.achiko.co
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005337/en/
Contact:
Axel Mühlhaus/ Dr. Sönke Knop Edicto GmbH Tel.: +49 69 905505-51 E-mail: achiko@edicto.de
Brigitte Kaps M: +41 (0) 79 289 2042 E-mail: pr@achiko.co
Shannon Chang VP Corporate Development, Achiko Limited E-mail: shannon.c@achiko.co
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom